Pulmonary Sarcoidosis Clinical Trial
— CLEAR LungOfficial title:
Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis
Verified date | October 2012 |
Source | Vanderbilt University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
Sarcoidosis is a granulomatous disease for which the molecular and immunologic association with mycobacteria continues to strengthen. The investigators are interested in conducting a proof-of-concept investigation of the effects of antibiotics on sarcoidosis resolution. The investigators hypothesize that pulmonary sarcoidosis will improve faster if patients are given antimycobacterial therapy, in addition to their standard therapy.
Status | Completed |
Enrollment | 15 |
Est. completion date | November 2010 |
Est. primary completion date | November 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Subjects with sarcoidosis will be enrolled as defined below. 1. Patients with sarcoidosis as defined by the ATS/ERS/WASOG statement on sarcoidosis as defined by the clinical presentation consistent with sarcoidosis, as well as biopsy finding granulomas, and no alternative for the cause of the granulomas, such as tuberculosis. 2. Evidence of parenchymal disease on chest radiograph (Stage II, III or IV) or Stage I disease by chest radiographs and evidence of abnormal spirometry. . Subjects with concurrent extrapulmonary sarcoidosis, particularly skin and eye involvement, can be enrolled. 3. FVC of >=45% and <=80% of predicted normal value at screening. 4. If female, subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or is using one of the following methods of birth control for the duration of the study and 90 days after study completion: 1. condoms, sponge, foams, jellies, diaphragm, or intrauterine device 2. contraceptives (oral or parenteral) for three months prior to study drug administration 3. a vasectomized sole partner 4. Females of childbearing potential must have a negative urine pregnancy test at screening visit. Exclusion Criteria: - 1. No consent/inability to obtain consent. 2. Age less than 18 years of age. 3. Inability to draw blood. 4. ALT or AST >5 times upper limit of normal (ULN) 5. Pregnancy or breast feeding. 6. Allergy to macrolides, quinolones or rifamycins. 7. Visual Impairment as defined by differentiating colors per personal history. 8. Family or personal history of long QT syndromes. 9. Patients receiving another interventional investigational drug for sarcoidosis within the 30 days prior to dosing 10. Use of any investigational medication within the past 28 days prior to study enrollment. 11. Subject has been hospitalized for infection or received IV antibiotics within the previous 2 months prior to baseline. 12. Subject has a history of tuberculosis at anytime or close contact with a person with active tuberculosis within the previous 6 months, or persistent or active infections requiring hospitalization or treatment with IV antibiotics, IV antiretrovirals, or IV antifungals within 30 days of baseline, OR oral antibiotics, antivirals, or antifungals for purpose of treating infection, within 14 days of baseline. 13. Subject has an active infection requiring systemic antibiotics at time of screening 14. Subject has a history of listeriosis, treated or untreated tuberculosis, exposure to individuals with tuberculosis. 15. Have a diagnosis of other significant respiratory disorder other than sarcoidosis that would complicate the evaluation of response to treatment 16. Patients otherwise unsuitable for participation in the opinion of the investigator. 17. No smoking for past one year. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
United States | Vanderbilt University School of Medicine | Nashville | Tennessee |
Lead Sponsor | Collaborator |
---|---|
Vanderbilt University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Absolute FVC From Baseline to Post Completion of 8 Weeks of Antibiotic Therapy. | The primary endpoint was improvement in absolute FVC from baseline to completion of therapy. Spirometry testing was performed using a standardized calibrated laptop spirometer, Flowscreen II USA Spirometer (VIASYS Healthcare Inc., Yorba Linda, CA). The volume accuracy of the spirometer was checked daily using a three liter calibration syringe. Each subject was given at least three attempts and the greatest measurement for absolute FVC and Forced Expiratory Volume (FEV1) at baseline, four week, and eight week assessments was recorded. | 8 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04064242 -
Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
|
Phase 2 | |
Terminated |
NCT00262132 -
Mycophenolate for Pulmonary Sarcoidosis
|
Phase 3 | |
Recruiting |
NCT05415137 -
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
|
Phase 3 | |
Recruiting |
NCT00001532 -
Role of Genetic Factors in the Development of Lung Disease
|
||
Completed |
NCT04318392 -
Breath Analysis in Patients With Suspected Sarcoidosis: The VOCs-IS Study
|
||
Active, not recruiting |
NCT03755245 -
Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis
|
N/A | |
Completed |
NCT01587001 -
The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
|
N/A | |
Recruiting |
NCT05890729 -
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT02824419 -
Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis
|
Phase 2/Phase 3 | |
Recruiting |
NCT06205121 -
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
|
Phase 2 | |
Completed |
NCT02200146 -
Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).
|
Phase 3 | |
Terminated |
NCT01732211 -
A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis
|
Phase 2 | |
Enrolling by invitation |
NCT06169397 -
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
|
Phase 2 | |
Active, not recruiting |
NCT05368883 -
Comparison of the Effects of One-Legged and Two-Legged Exercise Training on Exercise Capacity and Fatigue in Patients With Sarcoidosis
|
N/A | |
Not yet recruiting |
NCT05247554 -
Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis
|
Phase 3 | |
Completed |
NCT03599414 -
CASPA: CArdiac Sarcoidosis in PApworth
|
||
Recruiting |
NCT02188017 -
Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)
|
Phase 4 | |
Recruiting |
NCT06113991 -
Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis
|
||
Completed |
NCT00701207 -
Study of Nicotine Patches in Patients With Sarcoidosis
|
Early Phase 1 | |
Completed |
NCT03824392 -
Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis
|
Phase 1/Phase 2 |